The PI4KA antibody (phosphatidylinositol 4-kinase alpha) is a polyclonal or monoclonal immunoglobulin designed to detect the PI4KA protein, a key enzyme in phosphoinositide metabolism. PI4KA catalyzes the phosphorylation of phosphatidylinositol (PtdIns) to produce phosphatidylinositol 4-phosphate (PI4P), a precursor for signaling molecules like inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) . The antibody is widely used in molecular biology to study PI4KA’s role in membrane trafficking, organelle dynamics, and disease mechanisms, including hepatitis C virus (HCV) replication and leukemia chemoresistance .
The PI4KA antibody is validated for multiple experimental approaches:
Western Blot (WB): Detects PI4KA in cell lysates or tissue extracts. Recommended dilution: 1:1000–1:4000 .
Immunohistochemistry (IHC): Stains PI4KA in human placenta tissue, requiring antigen retrieval with TE buffer (pH 9.0) .
Immunoprecipitation (IP): Purifies PI4KA complexes for downstream analysis .
Immunofluorescence (IF)/ICC: Visualizes subcellular localization in MCF-7 cells .
| Species | Application | Title |
|---|---|---|
| Human | WB | Role of PI4KA in HCV replication |
| Mouse | WB | PI4KA-mediated mitochondrial division |
| Human | IHC | PI4KA expression in neurodevelopmental syndromes |
Host/Isotype: Rabbit IgG.
Reactivity: Human, mouse, rat.
Dilution Guidelines:
| Application | Dilution |
|---|---|
| WB | 1:1000–1:4000 |
| IP | 0.5–4.0 µg/1–3 mg lysate |
| IHC | 1:50–1:500 |
Host/Isotype: Rabbit IgG.
Reactivity: Human.
Applications: WB, ICC/IF.
Leukemia Chemoresistance: Depletion of PI4KA sensitizes drug-resistant leukemia cells to chemotherapy by disrupting the ERK/AMPK/OXPHOS axis. Cepharanthine (CEP), a PI4KA inhibitor, enhances this effect by destabilizing the PI4KA/TTC7/FAM126 complex .
HCV Replication: PI4KA interacts with NS5A to facilitate viral replication, making it a therapeutic target for antiviral strategies .
Neurodevelopmental Disorders: Biallelic PI4KA mutations are linked to hypomyelinating leukodystrophy and spastic paraplegia .